Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: "Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer | Journal of Experimental Clinical Cancer Research Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer Camerini et al. BioMed Central Camerini et al. Journal of Experimental Clinical Cancer Research 2011 30 38 http www.jeccr.com content 30 V38 11 April 2011 Journal of Experimental Clinical Cancer Research Camerini et al. Journal of Experimental Clinical Cancer Research 2011 30 38 http www.jeccr.eom content 30 1 38 RESEARCH Open Access Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer AIZ---1 1 2 1 1 1 Andrea Camerini Sara Donati Paolo Viacava Olimpia Siclari Cheti Puccetti Gianna Tartarelli Chiara Valsuani1 Filomena De Luca2 Leonardo Martini2 Andrea Cavazzana3 and Domenico Amoroso1 Abstract Background The human epidermal growth factor receptor 2 HER2 and p53 pathways may be involved in chemotherapy sensitivity and or resistance. We explore the value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast cancer. Methods HER2 and p53 expression was analysed in 36 median age 55 yrs range 37-87 metastatic breast cancer patients receiving docetaxel-based first-line chemotherapy. HER2 was determined by immunohistochemistry IHC and fluorescence in situ hybridization FISH p53 was tested by IHC. We correlate the expression of study parameters with pathologic parameters RECIST response and survival. The standard cut-off value of 2 was used to determine HER2 overexpression while p53 mean expression level was used to divide low high expressors tumors. Results Median time to progression and overall survival were 9 range 2 - 54 and 20 range 3 - 101 months. Overall response rate was 41.6 . Nine cases showed HER2 overexpression. HER2 was more frequently overexpressed in less differentiated p 0.05 and higher stage p 0.003 disease. Mean FISH-HER2 values were significantly higher in responder than in .